Edgar Filing: ARADIGM CORP - Form 8-K

ARADIGM CORP Form 8-K February 22, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 15, 2019

Aradigm Corporation

(Exact name of registrant as specified in its charter)

California (State or other jurisdiction

001-36480 (Commission

94-3133088 (IRS Employer

of incorporation)

File Number)

Identification No.)

3929 Point Eden Way, Hayward, California

94545

Edgar Filing: ARADIGM CORP - Form 8-K

(Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (510) 265-9000

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events

On February 21, 2019, Aradigm Corporation (the Company) announced via a press release that the Company received final minutes on February 15, 2019, from the U.S. Food and Drug Administration from a Type B meeting held on January 25, 2019. A copy of the Company s press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release of Aradigm Corporation dated February 21, 2019

SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 21, 2019

ARADIGM CORPORATION

By: /s/ John Siebert

Name: John Siebert

Title: Responsible Individual for Aradigm Corporation, Debtor and Debtor in Possession